Showing results (191-200 of 3,469) with videos related to
Sort By:
Pageof 347
Clinical Pharmacokinetics|August 1, 1987
Comparative bioavailability study of three sustained release quinidine formulationsW A Mahon, J S Leeder, M M Brill-Edwards, et al.Clinical Pharmacokinetics|March 12, 2021
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIIIFredrik Jonsson, Christophe Schmitt, Claire Petry, et al.Clinical Pharmacokinetics|March 6, 2021
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB DrugsMarieke G G Sturkenboom, Anne-Grete Märtson, Elin M Svensson, et al.Clinical Pharmacokinetics|October 5, 2019
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the ElderlyFelix Stader, Hannah Kinvig, Melissa A Penny, et al.Clinical Pharmacokinetics|October 5, 2019
A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model BuildingKhaled Abduljalil, Xian Pan, Amita Pansari, et al.Clinical Pharmacokinetics|June 1, 1987
Pharmacokinetics of nafimidone in patients with chronic intractable epilepsyD M Treiman, S GunawanClinical Pharmacokinetics|June 1, 1987
Bioavailability of bumetanide in grossly oedematous patientsG R Bailie, A Grennan, S WaldekClinical Pharmacokinetics|January 21, 2022
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin FormulationDominick J Angiolillo, Jayne Prats, Efthymios N Deliargyris, et al.Clinical Pharmacokinetics|July 17, 2015
A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in ChildrenKyle John Wilby, Sara Shabana, Mary H H Ensom, et al.Pageof 347